QuidelOrtho Corporation (NASDAQ:QDEL) Receives Average Rating of “Reduce” from Brokerages

Shares of QuidelOrtho Corporation (NASDAQ:QDEL) have been given an average recommendation of “Reduce” by the six brokerages that are covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a sell recommendation and three have given a hold recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $14.8750.

A number of analysts have commented on QDEL shares. Zacks Research lowered QuidelOrtho from a “hold” rating to a “strong sell” rating in a report on Tuesday, February 17th. UBS Group reissued a “neutral” rating and issued a $12.00 target price on shares of QuidelOrtho in a report on Thursday, May 7th. Wall Street Zen lowered QuidelOrtho from a “buy” rating to a “hold” rating in a report on Sunday, April 12th. Jefferies Financial Group lowered QuidelOrtho from a “buy” rating to a “hold” rating and reduced their target price for the stock from $35.00 to $12.50 in a report on Thursday, May 7th. Finally, Citigroup reduced their target price on QuidelOrtho from $30.00 to $13.00 and set a “neutral” rating for the company in a report on Wednesday, May 6th.

Institutional Trading of QuidelOrtho

A number of institutional investors and hedge funds have recently modified their holdings of QDEL. Invesco Ltd. increased its holdings in shares of QuidelOrtho by 87.0% in the 3rd quarter. Invesco Ltd. now owns 2,906,763 shares of the company’s stock worth $85,604,000 after purchasing an additional 1,352,503 shares in the last quarter. Newtyn Management LLC increased its holdings in shares of QuidelOrtho by 58.3% in the 3rd quarter. Newtyn Management LLC now owns 2,700,000 shares of the company’s stock worth $79,515,000 after purchasing an additional 994,332 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of QuidelOrtho by 101.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 1,755,401 shares of the company’s stock worth $50,134,000 after purchasing an additional 883,077 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of QuidelOrtho by 7.4% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 11,832,098 shares of the company’s stock worth $337,925,000 after acquiring an additional 819,908 shares during the period. Finally, Paradigm Capital Management Inc. NY grew its holdings in shares of QuidelOrtho by 84.1% in the first quarter. Paradigm Capital Management Inc. NY now owns 1,525,900 shares of the company’s stock worth $25,071,000 after acquiring an additional 697,010 shares during the period. Institutional investors own 99.00% of the company’s stock.

QuidelOrtho Stock Up 0.3%

QDEL stock opened at $14.13 on Tuesday. QuidelOrtho has a twelve month low of $9.92 and a twelve month high of $35.58. The company has a quick ratio of 0.80, a current ratio of 1.43 and a debt-to-equity ratio of 1.33. The firm has a market cap of $963.52 million, a PE ratio of -0.79 and a beta of 0.77. The business has a 50 day moving average of $13.03 and a 200 day moving average of $21.29.

QuidelOrtho (NASDAQ:QDEL) last posted its quarterly earnings data on Tuesday, May 5th. The company reported ($0.04) earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.41). QuidelOrtho had a negative net margin of 45.57% and a positive return on equity of 4.25%. The company had revenue of $619.80 million for the quarter, compared to the consensus estimate of $665.23 million. During the same period last year, the business earned $0.74 EPS. The firm’s quarterly revenue was down 10.5% on a year-over-year basis. QuidelOrtho has set its FY 2026 guidance at 1.800-2.000 EPS. On average, research analysts forecast that QuidelOrtho will post 1.83 EPS for the current fiscal year.

QuidelOrtho Company Profile

QuidelOrtho is a global diagnostics company formed through the merger of Quidel Corporation and Ortho Clinical Diagnostics. The combined entity develops, manufactures and markets a broad portfolio of rapid and high-throughput diagnostic solutions across immunoassay, molecular diagnostics and transfusion medicine. Its offerings span point-of-care platforms for acute care testing as well as large-scale automated systems designed for clinical laboratories and blood banks.

The company’s product range includes rapid antigen and antibody tests for infectious diseases, molecular assays utilizing nucleic acid amplification technology, and integrated immunodiagnostic analyzers.